Mesoblast Limited (MESO:NASDAQ) closed at $13.28 on October 16, 2026, down 4.80% on the day. The stock trades 38.2% below its 52-week high of $21.50 and 2.6% above its 52-week low of $12.94. Over the past year, it lost 22.2%. Mesoblast Limited is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -6.94% | -10.69% | -20.14% | -20.05% | -22.20% |
In 252 trading sessions since October 16, 2025, MESO closed higher on 118 days (47%). Its best day was March 25, 2026 (+9.29%) and its worst was January 12, 2026 (-10.93%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 3 times.
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on specialized cells, known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, orthopedic disorders, and oncologic/hematologic conditions. The company's lead product candidates include MPC-150-IM, a Phase 3 product candidate under investigation for the treatment of chronic congestive heart failure; MPC-06-ID, a Phase 3 product candidate under investigation for the treatment of chronic low back pain due to disc degeneration; MSC-100-IV, a Phase 3 intravenously-delivered product candidate, which is developed for the treatment of acute graft versus host disease following allogeneic bone marrow transplantation; and MPC-300-IV, an intravenously-delivered immunomodulatory product candidate for the treatment of chronic inflammatory conditions, including biologic-refractory rheumatoid arthritis, and diabetic nephropathy, which is u...
Find more stocks like MESO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.